Most Paragraf partnerships remain under strict confidentiality, and we are very excited for the day we can announce each of them. We are equally excited about the select few partnerships we can talk about and have highlighted them here.
Our Commercial Partnerships include the following components:
1.
Seamless business in a box with everything you need to get started
2.
Standard license & revenue sharing model
3.
Direct access to our BPUs enabling thousands of potential applications
4.
Dedicated support team to help you
Business in a box
Our starting package provides you with a BPU Benchtop that can read 16 chips at a time, 100 BPUs, a PC tower and two weeks of training and support – everything you need to get started building your service or product offering.
Access to innovation
Commercial Partners get unique access to existing infrastructure technology modules – greatly reducing development costs and timelines. New modules can be custom built for your application for an additional cost.
Your success is our success
Our Commercial Partnership team is committed to your success, from onboarding, assay development and analysis. We are here to get and keep your Powered by Paragraf offering up and running whether you are running assays internally or as a service to your customers.
Commercial partnerships
Biotome
Precision immunological diagnostics will be a future mainstay in everyday at home and in office testing. Biotome has created novel linear epitopes to assess stomach cancer risk (Helitope®) and SARS-CoV-2 infection (Covitope®). In an effort to provide rapid, at-home testing for stomach cancer and other disease states, Paragraf and Biotome have entered into a technology development partnership to usher this product to market. As Biotome’s epitope discovery platform is agnostic, the partnership sets the groundwork to provide tests to consumers in all facets of human health and wellness.
CRISPR QC
is actively using Paragraf’s CRISPR-Chip Technology to provide insight into key parameters of editing efficiency. Their assays can determine how well a gRNA is binding to a Cas enzyme, and how well a gRNA + Cas complex is binding to its intended target. This insight allows researchers to select only the best guides and Cas enzymes for their editing experiments – saving significant time and resources that would have otherwise been wasted on using ineffective reagents.
Research partnerships
Keck Graduate Institute
The birthplace of the CRISPR-Chip technology, Dr. Kiana Aran’s academic lab provides a great proving ground for application innovation for our platform. Keck Graduate Institute, a Claremont college, is one of the leading institutes in biomedical research, combining a strong entrepreneurial program with rigorous scientific research creates a nexus of innovation and development not just for technological applications but for the next-generation scientists. Paragraf is proud to continue to support our work with Keck Graduate Institute.
GTRI + DARPA
Paragraf is partnered with Georgia Tech Research Institute (GTRI) through a grant awarded by the Defense Advanced Research Projects Agency (DARPA) to develop a sensing platform to detect airborne SARS-CoV-2 particles as part of DARPA’s SensSARS program.
In addition to SARS-CoV-2 surveillance monitoring, Paragraf anticipates that with continued development, this real-time pathogen identification technology could have far-reaching civilian, public health, and defense applications, from agriculture and food supply monitoring to protection against biological or chemical warfare.
Pharmaceuticals
BPUs are currently being used in the pharmaceutical industry for drug discovery and has potential implications throughout the drug development process including kinetic characterizations, quality control, and therapeutic monitoring for all classes of drugs, including biologics.
Gene Editing
With the unique multiplexing capabilities and CRISPR-Chip™ technology, Paragraf’s BPU Platform can provide unique insight for gene editing workflows across agriculture, human health, and more. From identifying the best Cas enzyme + guide combinations to in-field or Point-of-Care confirmation of successful edits, Paragraf has the potential to provide tremendous value across this growing field that has the promise to revolutionize our lives.
Precision Agriculture
Our society depends on the development of sustainable agricultural practices, making precision agriculture a necessary component for our continued growth while safeguarding our environment. The BPU Platform holds promise for in-field genotyping of livestock and plants, runoff monitoring, pest and pathogen identification, new cultivar development, and more.
Diagnostics
Along with Biotome and other partners, the BPU Platform is actively being developed into disruptive screening, monitoring, and diagnostic tools for chronic conditions and infectious diseases. Paragraf’s all-electronic infrastructure provides unrivaled rapid sample-to-answer times, ultra-high sensitivity, and true-multiplexing, enabling new diagnostics that were only previously dreamed of.
Environmental Monitoring
Paragraf has partnered with GTRI and DARPA to develop a novel system for real-time monitoring of airborne SARS-CoV-2 particles. Paragraf technology applications run the gamut from water quality testing to identification of agricultural and industrial run-off to biowarfare agents.
Apply to partner with us!
Our growing network of partners operate in markets across diagnostics, research, agriculture, defense, and more – all leveraging Paragraf’s BPU Platform to build unrivalled products that create and disrupt their markets.
To apply for partnership, let us know a little bit about you, your team, the idea you want to commercialize with us, and what will make you our next great partner.